Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Schizophrenia- How can...

    Schizophrenia- How can Avtar therapy help?

    Written by Anjali Nimesh Nimesh Published On 2017-11-26T19:28:46+05:30  |  Updated On 26 Nov 2017 7:28 PM IST
    Schizophrenia- How can Avtar therapy help?

    An experimental therapy which involves a face-to-face discussion between a person with schizophrenia and an avatar representing their auditory hallucination may help reduce symptoms, when provided alongside usual treatment, according to a study published in The Lancet Psychiatry journal.




    The randomised controlled trial compared the avatar therapy to a form of supportive counseling (adapted specifically for the study). It found that avatar therapy was more effective at reducing hallucinations at 12-week follow-up, and had a large effect size.


    Further research to investigate the treatment's effectiveness in other healthcare settings will be needed, and so the treatment is not yet widely available.


    The study is the first large-scale randomized controlled trial of this type of therapy and was used in people with schizophrenia who had had persistent and distressing auditory hallucinations for more than a year, despite treatment. All participants continued to receive their usual treatment throughout the trial.


    Around 60-70% of people who have schizophrenia experience auditory hallucinations that are typically insulting and threatening. For most people, drug treatments reduce these symptoms, but approximately one in four people continue to experience voices. Cognitive behavioral therapy for psychosis (CBTp) can also be helpful but is a lengthy therapy with at times limited effects on voices.


    "A large proportion of people with schizophrenia continue to experience distressing voices despite lengthy treatment, so it is important that we look at newer, effective and shorter forms of therapy," says lead author Professor Tom Craig from King's College London, and the South London and Maudsley NHS Foundation Trust, UK.


    He adds: "Our study provides early evidence that avatar therapy rapidly improves auditory hallucinations for people with schizophrenia, reducing their frequency and how distressing they are, compared to a type of counseling. So far, these improvements appear to last for up to six months for these patients. However, these results come from one treatment center and more research is needed to optimise the way the treatment is delivered and demonstrate that it is effective in other NHS settings." [1]


    This study, which took place at Maudsley Hospital SHARP clinic and the Institute of Psychiatry, Psychology & Neuroscience at King's College London, involved 150 patients who had had schizophrenia for approximately 20 years and heard 3-4 voices on average. Of these, 75 people had the avatar therapy and the other 75 people had a form of supportive counseling designed for this study. They also continued with their usual antipsychotic medication throughout the trial.


    The avatar therapy took place over six sessions, with one 50-minute session each week. Before starting treatment, patients worked with the therapist to create a computerised simulation (avatar) of the voice they most wanted to influence -- including what the voice said, how it sounded, and how it could look. Therapy involved a three-way conversation between the patient, therapist, and avatar, with the therapist speaking as them and also voicing the avatar.


    In each session, after discussing the targets for that day's work, patients spent 10-15 minutes speaking face-to-face with the avatar, practicing standing up to it, correcting any misconceptions it had about them, and taking control of the conversation, so that power shifted from the avatar to the patient. The avatar came to recognize the patient's strengths and good qualities, and the patient's greater control and power in the relationship. The sessions were recorded, and an audio recording was given to the patient to take home to listen to when they heard the voices.


    The supportive counseling ran for the same number and length of sessions. It encouraged patients to discuss any issues of concern to them and aimed to lessen distress and discuss practical ways of improving their quality of life. As with avatar therapy, at the end of the session, each patient recorded a positive message to listen to during the following week.


    Assessments of the patients' auditory hallucinations were completed by researchers who were blind to which treatments patients had had.


    After 12 weeks, the avatar group's symptoms were rated as less severe than those who received counseling.


    People who had received avatar therapy also found their hallucinations less distressing and less powerful than people in the counseling group. Seven people who had the avatar therapy and two in the counseling group also reported that their hallucinations had completely disappeared after 12 weeks.


    The rapid improvements seen in the avatar treatment group were sustained at 24 weeks. However, during this time, hallucinations continued to become less frequent and less distressing for the counseling group also, likely because counseling could be a potentially useful therapy. As a result, there were no differences in outcomes between the two groups at 24 weeks.


    The researchers note some limitations, including that the counseling was conducted by graduate trainee therapists, which may impact its effectiveness. In addition, it is not yet clear whether avatar therapy will be easy for the wider mental health workforce to deliver, as the study was conducted in a center with expertise in treating psychosis and the avatar therapy was delivered by very experienced therapists.


    The researchers aim to conduct a cost-effectiveness analysis and investigate further the mechanisms of how the treatment reduces symptoms.


    Writing in a linked Comment, Dr Ben Alderson-Day, Durham University, UK, says "Technology can both obscure and enhance our view of reality, but in the case of AVATAR it seems to provide a powerful method of personifying and externalizing an otherwise internal and often intrusive phenomenon... Thinking of voices as entities or agents that can be engaged with9-a notion largely ignored or discouraged for many years within mainstream psychiatric thinking-raises a key question: who, or what is changing in AVATAR therapy? .... An emphasis on equipping the voice-hearer with responses, challenges, and answers of their own implies that the voice hearer is changing, but their voices might not be... On the other hand, the voices might change in terms of their content, valence, or power over the voice-hearer."



    Dr Ben Alderson Dayemphasisexperimental therapyKing's College LondonMaudsley HospitalschizophreniaThe Lancet Psychiatry journaltreatment
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok